Table 3.

Mean volumes of care and total direct costs in euros per patient per period in the treat-to-target (T2T) and usual care (UC) groups after two and three years of follow-up

	0-2 year
	T2T (n=261)		UC (n=213)			UC from 2006 (n=69)
	Volume	Costs	Volume	Costs	Difference in costs	Volume	Costs	Difference in costs
Consultations rheumatologist	10.4 ± 3.0	696 ± 199	10.3 ± 2.9	689 ± 195	7	10.2 ± 3.6	683 ± 239	13
Consultations nurse	8.8 ± 3.0	588 ± 200	7.8 ± 1.9†	522 ± 127†	66	6.6 ± 2.0†	438 ± 134†	150
Telephonic consultations	1.3 ± 1.8	34 ± 46	0.6 ± 1.4†	16 ± 36†	18	1.1 ± 1.9	29 ± 48	5
Hospital admissions	0.4 ± 2.7	178 ± 1,208	1.1 ± 4.2†	521 ± 1,901†	-343	0.3 ± 1.6	158 ± 714	20
Medication
DMARDs/other		174 ± 165		249 ± 340	-75		166 ± 119	8
Anti-TNF		3,121 ± 7,162		1,730 ± 4,905†	1,391		1,877 ± 5,086	1244
Total		4,791 ± 7,436		3,727 ± 5,773	1,064 (1,026 to 1,121)‡		3,351 ± 5,179†	1440 (1,387 to 1479)‡
	0-3 year
	T2T (n=127)		UC (n=180)			UC from 2006 (n=45)
	Volume	Costs	Volume	Costs	Difference in costs	Volume	Costs	Difference in costs
Consultations rheumatologist	13.7 ± 3.3	917 ± 220	13.6 ± 3.3	909 ± 224	8	12.5 ± 3.8	838 ± 253†	79
Consultations nurse	12.1 ± 3.6	809 ± 244	8.9 ± 1.7†	596 ± 117†	213	8.4 ± 2.2†	565 ± 145†	244
Telephonic consultations	1.9 ± 2.1	49 ± 54	0.8 ± 1.7†	21 ± 45†	28	1.7 ± 2.5	43 ± 64	6
Hospital admissions	0.5 ± 3.2	215 ± 1,441	1.6 ± 5.0†	748 ± 2,263†	-533	0.8 ± 2.7	364 ± 1,217	-149
Medication
DMARDs/other		260 ± 335		423 ± 612†	-163		259 ± 174	1
Anti-TNF		4,160 ± 10,685		4,175 ± 10,070	-15		5,488 ± 11,528	-1,328
Total		6,410 ± 10,845		6,872 ± 11,033	-462 (-513 to -350)‡		7,558 ± 11,649	-1,148 (-1241 to -1075)‡

Volumes are the mean ± standard deviation (SD).

Anti-TNF, anti-tumour necrosis factor; CI, confidence interval; DMARDs, disease-modifying antirheumatic drugs.

† P < 0.05 for differences between groups (T2T versus UC). ‡ 95% confidence interval bootstrapped.